Effect of Helicobacter pylori infection on the first-line treatment outcomes in patients with immune thrombocytopenic purpura

dc.authorscopusidÖmer Ekinci / 57194114271en_US
dc.contributor.authorDoğan, A.
dc.contributor.authorEkinci, Ömer
dc.contributor.authorEbinc, S.
dc.date.accessioned2022-07-05T14:24:20Z
dc.date.available2022-07-05T14:24:20Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesien_US
dc.description.abstractOBJECTIVE: Helicobacter pylori (H. pylori) eradication therapy is known to increase the platelet count, but in immune thrombocytopenic purpura (ITP), the effect of H. pylori infection on the response to treatment is not clear. This study aims to determine whether the response to the first-line treatment is affected by the states of H. pylori-positivity and -negativity in ITP patients. PATIENTS AND METHODS: Adult newly diagnosed or chronic ITP patients who had not received eradication therapy for H. pylori infection were included. Characteristics of the patients, presence and severity of bleeding, initial platelet count, administered treatments, and treatment response rates were inspected. RESULTS: Of 119 total patients, 66 (55.5%) were female, 32 (26.9%) were H. pylori-positive, 87 (73.1%) were H. pylori-negative. H. pylori-positive and H. pylori- negative groups were not significantly different in terms of age (p=0.127), gender (p=0.078), diagnosis status (p=0.094) and the distribution of bleeding symptoms (p=0.712). The most common treatment was standard-dose steroid in both groups (62.5% vs. 68.9%, p=0.524). Rates of complete response, partial response, no response were comparable for the two groups (respectively, 75% vs. 73.6%, and 18.8% vs. 19.5%, and 6.2% vs. 6.9%), and there was no significant difference between the groups (p=0.283). CONCLUSIONS: It can be stated, according to the present study, that in ITP patients in whom treatment is indicated, the response to the firstline treatment without the administration of H. pylori eradication therapy is similar between H. pylori-positive and H. pylori-negative patients. © 2022 Verduci Editore s.r.l. All rights reserved.en_US
dc.identifier.citationDogan, A., Ekinci, O., & Ebinc, S. (2022). Effect of helicobacter pylori infection on the first-line treatment outcomes in patients with immune thrombocytopenic purpura. European Review for Medical and Pharmacological Sciences, 26(11), 3995-4000. doi:10.26355/eurrev_202206_28970en_US
dc.identifier.doi10.26355/eurrev_202206_28970en_US
dc.identifier.endpage4000en_US
dc.identifier.issn1128-3602en_US
dc.identifier.issue11en_US
dc.identifier.scopus2-s2.0-85132720859en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage3995en_US
dc.identifier.urihttps://doi.org/10.26355/eurrev_202206_28970
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2974
dc.identifier.volume26en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorEkinci, Ömer
dc.language.isoenen_US
dc.publisherVerduci Editore s.r.len_US
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFirst-Line Treatmenten_US
dc.subjectHelicobacter Pylorien_US
dc.subjectImmune Thrombocytopenic Purpuraen_US
dc.titleEffect of Helicobacter pylori infection on the first-line treatment outcomes in patients with immune thrombocytopenic purpuraen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
3995-4000.pdf
Boyut:
340.24 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: